Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-11 5:55 pm Purchase | 2021-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | MILLER RICHARD A MD | 2,607,148 5.450% | 427,589 (+19.62%) | Filing History |
| 2022-01-18 4:55 pm Purchase | 2021-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Integrated Core Strategies (US) LLC | 2,920,059 6.300% | 403,531 (+16.04%) | Filing History |
| 2021-12-06 4:44 pm Purchase | 2021-12-01 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Integrated Core Strategies (US) LLC | 2,516,528 5.400% | 487,927 (+24.05%) | Filing History |
| 2021-11-03 3:03 pm Unchanged | 2021-11-02 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 6,943,654 14.900% | 0 (Unchanged) | Filing History |
| 2021-10-22 4:36 pm Purchase | 2021-10-12 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Integrated Core Strategies (US) LLC | 2,028,601 4.800% | 2,028,601 (New Position) | Filing History |
| 2021-10-05 1:03 pm Sale | 2021-09-30 | 13G | Corvus Pharmaceuticals, Inc. CRVS | EcoR1 Capital, LLC | 81,077 0.200% | -5,000,000 (-98.40%) | Filing History |
| 2021-09-30 4:05 pm Purchase | 2021-09-20 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Venrock Healthcare Capital Partners II, L.P. | 3,427,461 8.100% | 3,427,461 (New Position) | Filing History |
| 2021-09-23 3:14 pm Purchase | 2021-09-22 | 13G | Corvus Pharmaceuticals, Inc. CRVS | EcoR1 Capital, LLC | 5,081,077 12.000% | 1,501,700 (+41.95%) | Filing History |
| 2021-09-22 5:21 pm Sale | 2021-09-20 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 6,943,654 16.400% | -1,109,644 (-13.78%) | Filing History |
| 2021-09-22 08:31 am Purchase | 2021-09-21 | 13G | Corvus Pharmaceuticals, Inc. CRVS | TANG CAPITAL PARTNERS LP | 3,736,184 8.800% | 3,736,184 (New Position) | Filing History |
| 2021-08-04 5:21 pm Unchanged | 2021-08-02 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 8,053,298 19.000% | 0 (Unchanged) | Filing History |
| 2021-05-11 4:06 pm Purchase | 2021-05-04 | 13G | Corvus Pharmaceuticals, Inc. CRVS | EcoR1 Capital, LLC | 3,579,377 8.500% | 3,579,377 (New Position) | Filing History |
| 2021-02-17 5:08 pm Purchase | 2021-02-17 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 8,053,298 21.980% | 1,285,714 (+19.00%) | Filing History |
| 2021-02-12 9:18 pm Purchase | 2020-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | MILLER RICHARD A MD | 2,179,559 7.500% | 220,417 (+11.25%) | Filing History |
| 2021-02-12 4:09 pm Sale | 2020-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | BIOTECHNOLOGY VALUE FUND L P | 2,898,797 9.990% | -22,380 (-0.77%) | Filing History |